T-regulatory cell 1 (Tr1) are low proliferating peripherally-induced suppressive T cells. Engaging CD3 and CD46 on human CD4 + T cells induces a Tr1-like phenotype.
INTRODUCTION

Regulatory T cells are potent cells that inhibit self-antigen and innocuous-foreign
antigen-specific adaptive immune effectors (1) (4) . Recently, it has been reported that the minimal engagement of the TCR and CD46 induces human CD4 + T cells with a Tr1-like phenotype, able to suppress T cell proliferation through the production of IL-10 (9). CD46 is a complement regulator that we initially described for its potential to co-stimulate T cells (10, 11).
Nevertheless, unlike Tr1 cells, CD3/CD46-induced Tr1-like cells were described to exhibit a strong and prolonged proliferation (9).
Using low concentration of anti-CD3 to better assess for the co-stimulatory role of CD46, we differentiated weakly proliferating human Tr1 cells. We report here that the poor proliferation of CD3/CD46-induced Tr1 cells results from a defect in cell cycle progression and an increased sensitivity to cell death, both mechanisms being explained by a defective Akt pathway.
MATERIALS AND METHODS
Cells and antibodies
Human CD4 + T cells (>95% purity) were purified from blood donors (EFS Lyon, France) as described (10) and cultured in complete RPMI. For cell culture, the mAbs used were: anti-CD3, (OKT3, 1µg/ml, otherwise indicated); anti-CD46, (20.6, 10µg/ml); anti-CD28, (CD28.2, 10µg/ml) (all Abs purified in our laboratory); anti-CD95, (ZB4, 1 g/ml); isotype control (10µg/ml) (both from Beckman-Coulter and the rabbit polyclonal Abs specific for Erk1/2 (both from Upstate Biotechnology, Lake Placid, NY) and anti-actin (Sigma-Aldrich, St Quentin Fallavier, France).
Cell stimulation, proliferation and cytokine production analysis
Naive CD4 + T cells were cultured on plates coated with the indicated mAbs, at a concentration of 1x10 6 T cells/ml. When indicated, 10 U/ml of recombinant human IL-2 was added (a gift from Dr. Demetrier-Caux). 
Flow cytometry
For cell death assessments, T cells were labeled with 67nM of ToPro-3 (Molecular Probes, Leiden, The Netherlands). To determine cell division numbers, 2x10 7 T cells/mL (RPMI 2%FCS) were kept at 37°C for 13 min after addition of 0,5M CFSE (Molecular Probes), washed 3 times in cold RPMI 10%FCS and cultured for various periods of time before being analyzed by FACS. For cell cycle analysis, 0,5x10 6 CD4 + T cells were labeled 30min at room-temperature with 20 M 7-Aminoactinomycin D (7-AAD) in 500 L of 0,03% saponin/NASS Buffer (100mM phosphate-citrate buffer pH=6, 150mM NaCl, 5mM EDTA, 0,5% BSA). Cells were kept on ice 5min and 5 M PY (Sigma) was added prior analysis.
Western blot analysis
T cells were lysed in ice-cold buffer, the protein concentration from each lysate determined (Micro-BCA kit, Pierce Perbio) and 50 µg of proteins were analyzed by SDS-PAGE and Western blotting as described (11). 
Real-time RT-PCR
RESULTS AND DISCUSSION
Weakly proliferating CD3/CD46-differentiated Tr1-like cells
We previously reported that CD46 provides a co-stimulatory signal for human T cells (10). It was subsequently described that, in addition, CD46 favors the differentiation of human Tr1-like regulatory cells (9). To allow for an efficient assessment of the role of CD46 co-stimulation in Tr1 cell differentiation, we stimulated freshly purified naive human CD4 + T cells with an immobilized non-saturating concentration of anti-CD3 (1 g/ml) in combination with anti-CD46 (Fig. 1A left panel) . Such CD3/CD46-stimulated T cells displayed a weak proliferation that was reminiscent to the Tr1 cell phenotype. On the contrary, as previously reported (9), higher concentrations of anti-CD3 did allow for a more sustained proliferation of CD3/CD46-stimulated compared to CD3/CD28-stimulated (control effector) T cells (Fig. 1A ).
We then ensured that using a limiting concentration of anti-CD3 induced functional We then examined the down regulation of the inhibitor of cell cycle progression p27/Kip1. Whereas CD28-co-stimulated T cells degraded p27/Kip1 as soon as day 1 post activation and maintained such degradation up to day 5, CD46-co-stimulated T cells only partially down regulated p27/Kip1 mainly on day 3 (Fig. 2B ). Since the degradation of p27/Kip1 is required for cells to progress from the G0/G1 phase to the S phase of the cell cycle (13), we wondered if CD3/CD46-stimulated T cells might have a defect in cell cycle progression. Staining cells with 7-AAD and PY revealed that by day 3 of culture CD3/CD46-stimulated T cells accumulated in the G0/G1 phase more abundantly than CD3/CD28-stimulated T cells (Fig. 2C ). This result indicates that the lack of sustained proliferation of CD3/CD46-generated Tr1-like cells is due, at least partially, to a G0/G1 blockage in their cell cycle progression.
Cell death sensitivity of dividing Tr1-like cells due to abortive proliferation
In addition to a cell-intrinsic defect in cell cycle progression, the lack of sustained Tr1-like cell proliferation could result from an increased sensitivity of these cells to death. Therefore, we examined the survival of proliferating CD3/CD46-stimulated T cells by determining the rate of dead cells by ToPro-3 staining after 3, 4 and 5 days of culture. Until day 4, CD4 + T cells displayed comparable level of apoptosis whatever the nature of the stimulation, CD3, CD3/CD28 or CD3/CD46 (Fig. 3A) . However, by day 5 more than 30% of the CD3/CD46-stimulated cells were apoptotic whereas less than 20% of cells in all other conditions of culture were ToPro-3 + . We then asked if the sensitivity to death of Tr1-like cells correlated with their proliferation since Tr1 are low proliferating cells. Indeed, the most the 5 days CD3/CD46-stimulated T cells divided, the most they underwent apoptosis with more than 40% of the cells that divided 5 times that were ToPro-3 + (Fig. 3B) . On the contrary, whatever the number of division considered, we constantly observed about 20% of CD3/CD28-stimulated T cells that were ToPro-3
Since Tr1-like cells do not produce IL-2, it was possible that CD3/CD46-stimulated T cells died because of the absence of a survival signal provided by IL-2. However, adding IL-2 to the CD3/CD46-stimulated T cell culture only marginally rescued differentiated Tr1-like cells from death (Fig. 3C) . Therefore, the defective proliferation of Tr1-like cells is due not only to a limited potential of proliferation but also to an increased sensitivity to cell death.
Likewise, proliferating T cells may become sensitive to death through a Fas/FasLmediated mechanism (14). However, preventing the interaction between Fas and FasL with a blocking anti-Fas mAb did not rescue CD3/CD46-stimulated CD4 + T cells from death (Fig. 3D) .
Finally, the death of CD3/CD46-stimulated T cells could result from a defect of Bcl-2 and/or Bcl-xL expression, two anti-apoptotic genes crucial for T cell survival (15) . to be a privileged target since Akt activation is crucial in CD28 co-stimulation dependant T cell proliferation and survival (16, 17) . We looked for Akt activation by western blot using an activated-Akt specific mAb. Very interestingly, only marginal activation of Akt was detected from lysate of T cells stimulated for 3 days with CD3
and CD46 (Fig. 4A) . On the contrary, as expected Akt was heavily activated in 3 days CD3/CD28-stimulated T cells and such activation was strongly maintained until day 5. The defective Akt phosphorylation pathway in CD46-induced Tr1 cells was specific since the Erk1/2 MAPK pathway was equivalently phosphorylated from 3 day CD3/CD46-and CD3/CD28-stimulated naive CD4 + T cells (Fig. 4A) . Moreover (19), however we and others reported that the ERK pathway is fully activated in CD3/CD46-stimulated T cells (Fig. 4A, 11, 20) .
Second, the Akt pathway is required to optimally degrade p27/Kip1 (16), an inefficient event of Tr1-like cells, that is necessary for an efficient T cell proliferation.
Third, the Akt pathway is crucial for the antigen-induced T cell survival and regulates the Survivin expression (17, 18) , two processes that we show here to be defective in Cell 78:59-66.
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Abbreviation
Tr1: T-regulatory cell 1. 
